Treatment of psoriasis has been revolutionized with the introduction of biologics and today several biologics, target specific cytokines in the psoriasis pathogenesis, including drugs targeting tumor necrosis factor alpha (TNF-α), interleukin (IL)-12p40, IL-17, and IL-23p19 [1]. This evidence concerns the gene IL23A and psoriasis.